Case Study: Stem Cell Therapy in Treating Spinal Cord Injuries

Abstract

Spinal cord injuries are an abnormal alteration of one's life that may lead to serious disability for which little treatment is available. So far, the possibility of regeneration of damaged tissues and restoration of neurological function has been reported in stem cell therapy, which is a promising therapeutic approach. The case is reported of a 35-year-old man who had suffered a traumatic spinal cord injury and received stem cell therapy as part of his care. The development of the patient, from diagnosis to therapy, and the clinical results of the intervention are discussed as illustrations of the potential of stem cell therapy in SCI management.

Introduction

SCI most often occurs due to trauma, and, as such, it is characterized by severe, irreparable loss of function, including paralysis, loss of sensation, and disruption in autonomic functions. The historical way of managing the injury provides stabilization of the wound, prevention of further damage, and maximization of rehabilitation efforts; however, such treatment does not result in any certain cure for loss of function.

Stem cell therapy has recently emerged as a novel approach in regenerative medicine, with a promise to eventually help replace damaged cells, reduce inflammation, and grow new neurons. For this case study, an outline is provided of how stem cell therapy may be used to treat a 35-year-old male patient who sustained a spinal cord injury due to a motor vehicle accident: Clinical course, treatment response, and results after the treatment.

Patient Information

• Patient: John Roberts, 35-year-old male

• Medical History: No significant medical history before the injury. The patient was physically active and had no prior neurological or spinal issues.

• Presenting Concerns: The patient suffered a complete thoracic spinal cord injury (T6 level) following a motor vehicle accident. He experienced an immediate loss of motor function and sensation in the lower extremities and was diagnosed with paraplegia.

Clinical Findings

On presentation, the patient was entirely dependent on assistance with all functions, had no motor or sensory function below T6, and therefore had a complete spinal cord injury. MRI of the spine also revealed that the patient had a traumatic injury with massive compression and damage to the thoracic portion of the spinal cord. Neurological examination classified the injury into an AIS grade A; complete absence of both motor and sensory function below the level of injury is a hallmark for the AIS grade A.

Timeline

1. Day 1: Sustained spinal cord injury from motor vehicle accident. Immediate admission to the hospital.

2. Week 1: Stabilization surgery to decompress the spine and prevent further damage.

3. Month 1: Initiated rehabilitation with physical and occupational therapy.

4. Month 3: Referred for stem cell therapy as part of an experimental treatment.

5. Month 4: Stem cell therapy administered via intrathecal injection.

6. Month 7: First follow-up, showing some sensory improvement in the lower limbs.

7. Month 12: Continued rehabilitation with gradual improvement in muscle tone and limited voluntary movement in lower extremities.

Diagnostic Assessment

Diagnostic imaging by MRI and CT scan was done following the injury to establish the level of damage to the spinal cord. Through the imaging process, it emerged that the patient sustained a complete T6 spinal cord injury with significant spinal cord compression. The patient underwent blood tests as well as other assessments to establish his eligibility for stem cell therapy.

Before the stem cell therapy performance, comprehensive neurological assessments were carried out on the patient using the ASIA scale to document the degree of impairment. The degree of impairment in the patient was assessed to evaluate if a possibility of spontaneous recovery existed before initiating treatment with stem cells.

Follow-Up and Outcomes

Three months after the stem cell treatment, the patient manifested slight improvement in sensory function in his lower limbs, specifically in regions just immediately below the areas where the injury had taken place. Motor function was still restricted. Six months post-treatment, the patient persisted, presenting with some improvement in the aspect of sensory ability and increased muscle tone of the lower extremities but voluntary movement was minimal.

By the 12th month after injury, the patient was able to start with a slight voluntary movement of his legs, and there was enhancement of physical therapy at this stage, taking advantage of the minor accomplishment in terms of motor function. Generally, the quality of life improved as he regained a level of autonomy in his daily activities with assistive devices.

Discussion

The neurogenesis and reduction of inflammation at the site would have enabled the therapy to regenerate damaged tissues along the spinal cord. In this particular case, the patient was given a form of treatment whereby stem cells derived from his own body were processed and introduced into the cerebrospinal fluid surrounding the injured spinal cord.

The gains were not dramatic, but the patient did show progressive improvement in sensory and motor function over time. Small recoveries underscore the potential as well as the limitations of stem-cell therapies in spinal cord injuries, significant areas of research. Nevertheless, neurological gains from therapy would have been limited without the intervention. Indeed, the therapy was also well-tolerated; no major adverse effects were noted.

This case underlines the need for further research in attempts to make such stem cell therapies available and optimal for patients with SCI. Limitations of this currently include variability in patient response and degree of recovery. The integration must also be made with intensive rehabilitation to maximize the chances of recovery.

Takeaway

Stem cell therapy holds significant potential in the treatment of spinal cord injury patients, especially in helping to improve sensory recovery and in helping improve muscle tone. It does not cure, but it might help in improving a better outcome when combined with some of the traditional rehabilitation techniques. Even in John Roberts's case, incremental benefits from stem cell therapy underpin the need for early intervention and comprehensive care.

Patient’s Perspective

When I first heard about stem cell therapy, I knew it was experimental but I had to try something more," she says, "because it's been a slow process, at least seeing even the littlest of improvements in my condition gives me hope. Of course, I'm not going to ever regain full function. Every bit makes a big difference in my life."

Conclusion

There have been several researchers emerging promising treatment possibilities for patients with SCI to improve their recovery and long-term outcomes through stem cell therapy. As a case report, it focuses on using stem cells in the regeneration of damaged neural tissue with the rehabilitation of motor functions as well as the improvement of the quality of life. While this remains in its developing stages, preliminary data even suggest good functional improvements in most patients. However, it has to be kept in mind that the stem cell therapy for SCI is still in the experimental phase, and further studies will be required before it is understood clearly, whether this treatment modality becomes safe and efficient long-term treatment. The patient marked progress after the treatment; however, patients might respond variably, so individualized treatment plans and strict follow-up evaluation become essential.

In summary, then, stem cell therapy represents an emerging frontier in SCI treatment, and ongoing clinical trials and advancements in regenerative medicine may alter the face of prognosis for these patients who suffer injuries that alter their lives. Though obstacles include issues of immune rejection, ethical problems, and high costs, the benefits in potential gains in any case make the area of stem cell therapy something of hope, promising as something significant for therapeutic strategies down the road of spinal cord injury rehabilitation.

References

1. Assinck, P., Duncan, G. J., Hilton, B. J., Plemel, J. R., & Tetzlaff, W. (2017). Cell transplantation therapy for spinal cord injury. Nature Neuroscience, 20(5), 637-647.

2. Tewarie, R. S., Hurtado, A., Bartels, R. H. M. A., Grotenhuis, A., & Oudega, M. (2012). Stem cell-based therapies for spinal cord injury. Journal of Spinal Cord Medicine, 35(1), 8-18.

3. Lee, J. H., Lee, S. M., Kim, J. E., Park, J. H., & Chung, J. Y. (2020). Clinical application of stem cell-based therapies for spinal cord injuries: Current evidence and future perspectives. Journal of Neurosurgery Spine, 33(1), 76-87.

4. Tabakow, P., Jarmundowicz, W., Czapiga, B., Fortuna, W., Miedzybrodzki, R., & Raisman, G. (2014). Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. Cell Transplantation, 23(12), 1631-1655.

5. Anderson, K. D., Guest, J. D., Dietrich, W. D., Bunge, M. B., & Pearse, D. D. (2011). Stem cell therapies for spinal cord injury. Journal of Neurotrauma, 28(8), 1379-1399.

6. Silva, N. A., Sousa, N., Reis, R. L., & Salgado, A. J. (2014). From basics to clinical: A comprehensive review on spinal cord injury. Progress in Neurobiology, 114, 25-57. DOI: 10.1016/j.pneurobio.2013.11.002

7. Curtis, E., Martin, J. R., Gabel, B., Sidhu, N., Rzesiewicz, T. K., Mandeville, R., … & Lucas, E. (2018). A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell, 22(6), 941-950.e6.DOI: 10.1016/j.stem.2018.05.014

8. Kwiecien, J. M., Yaron, J. R., Zhang, L., & Chowdhury, S. R. (2020). Spinal cord injury: Pathophysiology, therapeutic targets, and drug delivery strategies. Journal of Neurotrauma, 37(22), 2455-2464. DOI: 10.1089/neu.2019.6742

9. Fehlings, M. G., Wilson, J. R., Tetreault, L. A., Aarabi, B., Anderson, P., & Harrop, J. S. (2017). A clinical practice guideline for the management of patients with acute spinal cord injury: Recommendations on the use of methylprednisolone sodium succinate. Global Spine Journal, 7(3_suppl), 203S-211S. DOI: 10.1177/2192568217703085

10. Filli, L., & Schwab, M. E. (2015). The role of axon growth inhibition in spinal cord injury recovery. Frontiers in Neuroscience, 9, 627. DOI: 10.3389/fnins.2015.00627

11. Li, J., Lepski, G., & Greiner, C. (2019). Advances in stem cell-based therapies for spinal cord injuries. Current Opinion in Neurology, 32(5), 695-701. DOI: 10.1097/WCO.0000000000000711.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors